Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration, enhancing its product portfolio in traditional Chinese medicine [1] Group 1 - The prescription for Banxia Xiexin Decoction Granules is derived from Zhang Zhongjing's "Shanghan Lun" from the Han Dynasty and is included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The function and indications of Banxia Xiexin Decoction Granules include balancing cold and heat, dispersing masses, and alleviating fullness without pain, as well as symptoms such as vomiting, intestinal rumbling, and diarrhea [1] - The acquisition of the drug registration certificate for Banxia Xiexin Decoction Granules further enriches the company's range of traditional Chinese medicine products and will synergize with existing core products [1]

Group 1 - The core point of the article is that Guangyuyuan has received approval from the National Medical Products Administration for the registration of Banxia Xiexin Decoction granules, which is a significant development for the company [1] - Guangyuyuan's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 89.39%, while other businesses contribute 3.85%, and health wine accounts for 3.29% [1] - As of the report, Guangyuyuan's market capitalization stands at 8.9 billion yuan [1] Group 2 - The article also mentions that the real estate sector is facing challenges, with a notable 2 billion yuan debt maturing and ongoing negotiations for debt extension, alongside over 10 billion yuan in public debts due next year [1]

证券代码：600771 证券简称：广誉远 编号：临 2025-021 广誉远中药股份有限公司 关于控股子公司获得药品注册证书的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广誉远中药股份有限公司（以下简称"公司"）控股子公司山西广誉远国药 有限公司（以下简称"山西广誉远"）收到国家药品监督管理局核准签发的半夏泻心汤 颗粒的《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品通用名称：半夏泻心汤颗粒 剂型：颗粒剂 规格：每袋相当于饮片 27.77g 注册分类：中药 3.1 类（按古代经典名方目录管理的中药复方制剂） 药品批准文号：国药准字 C20250017 药品注册证书编号：2025S03819 上市许可持有人：山西广誉远国药有限公司 米内网三大终端六大市场数据显示，半夏泻心汤颗粒所属的胃肠道类用药（中成药） 在 2024 年国内相应零售和医疗终端市场销售金额共计 106.15 亿元，同比上升 1.01%。 经检索国家药品监督管理局官方网站信息，截至目前，国内尚无企业取得半夏泻心汤颗 粒的药 ...

Group 1 - The company has announced a shareholder return plan for 2024-2026, which includes conditions for profit distribution such as positive net profit and sufficient cash flow [1] - The company aims to achieve cumulative distributable profits turning positive and will ensure that the annual financial report receives an unqualified audit opinion [1] - The company will actively distribute profits in cash, provided there are no major investment plans or significant cash expenditures, ensuring normal operations and long-term development [1] Group 2 - The company emphasizes "growth" as its core strategy and is focused on improving operational quality through various measures [1] - Initiatives include optimizing the channel network, upgrading product structure, enhancing brand value, and increasing operational efficiency to drive performance improvement [1]

证券日报网讯12月19日，广誉远（600771）在互动平台回答投资者提问时表示，二级市场股价受多重因 素影响波动，请理性看待，谨慎投资。公司严格按照相关监管要求履行信息披露义务，截至目前无应披 未披事项。 ...

Core Viewpoint - The article highlights how Guangyuyuan, a nearly 500-year-old Chinese time-honored brand, continues to thrive by embracing innovation while adhering to traditional practices in the face of industry competition and technological advancements [5]. Group 1: Traditional Practices - Guangyuyuan maintains a commitment to traditional production methods, such as the three-year sun-drying process for vinegar, which ensures the efficacy of its products [6]. - The company has developed unique processing techniques over time, including various methods like steaming, frying, and sun-drying, which are essential for enhancing the medicinal properties of their products [6][7]. - Guangyuyuan is one of the few traditional Chinese medicine companies with uninterrupted inheritance, boasting 20 major intangible cultural heritage projects and 30 inheritors [7]. Group 2: Product Portfolio - The core products of Guangyuyuan, including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan, account for over 90% of the company's total revenue, with most being prescription drugs [7]. - The company has introduced innovative products like the "Youth Cannon" version of Gui Ling Ji, which has seen significant sales growth during promotional events [8]. Group 3: Business Strategy and Growth - In the first three quarters of 2025, Guangyuyuan achieved a revenue of 1.061 billion yuan, marking an 18.71% year-on-year increase, with a profit growth of 31.73% [9]. - The company aims to expand its market presence through the revitalization of traditional products, the development of health products, and strategic marketing initiatives [9][10]. - Guangyuyuan has established a new positioning and mission across its various business segments, focusing on academic standing, high-end health branding, and market scale enhancement [11].

广誉远（600771.SH）12月9日在投资者互动平台表示，您好，感谢您的关注。公司产品龟龄集（30 粒）的官方指导零售价为598元/盒，公司并未对其进行调整。线上店铺销售价格受平台活动政策、满减 优惠及新人福利等多项因素影响，价格在合理区间内波动属正常情况。 每经AI快讯，有投资者在投资者互动平台提问：请问龟龄集（30粒）官方市场指导零售价是多少一 盒？微店广誉远大健康商城销售价为528元/盒，请问最近销售价是否提价了？ （记者 曾健辉） ...

证券日报网讯12月9日，广誉远（600771）在互动平台回答投资者提问时表示，目前，公司管理团队稳 定，各项工作均有序推进，不存在应披未披事项。 ...

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：根据中药材天地网发布的公司公开招标采购的大宗药 材统计，今年采购药材量达到47万余千克，是2024年采购量的3.6倍，是因为公司核心药品产量增加还 是代工大健康品增加？ 广誉远（600771.SH）12月9日在投资者互动平台表示，您好，感谢您的关注。公司采购各种药材均是 生产自有产品，采购量是综合考虑生产供应、价格行情、需求响应和战略考量等因素实施的。 ...

Core Viewpoint - The news highlights the passing of Guan Ping, a prominent figure in the Chinese pharmaceutical industry, and acknowledges his significant contributions to the sector and various companies he worked with [2][4]. Group 1: Guan Ping's Contributions - Guan Ping was recognized as a senior professional manager in the Chinese pharmaceutical industry, earning accolades such as the "Top Ten Professional Managers" and "Top Ten Pharmaceutical Elites" [4]. - He played a pivotal role in the marketing of major OTC products like Calcium D and Bai Jia Hei, earning the title "Prince of OTC" for his achievements [4][5]. - His career began in 1988 at Xi'an Janssen, where he became the second local pharmaceutical representative, marking the start of his impactful journey in the industry [4]. Group 2: Career Milestones - A significant turning point in Guan Ping's career occurred in 1997 when he joined Wyeth as a regional marketing director, transitioning the company’s focus from hospital sales to the OTC retail market [4][5]. - Under his leadership, sales of Calcium D increased by nearly 20% in 1998, surpassing hospital sales in the retail market [5]. - In 2001, he joined Dongsheng Technology as a director and vice president, where he successfully revitalized the Bai Jia Hei brand, increasing its sales from over 2 million to more than 200 million [5][6]. Group 3: Innovative Strategies - Guan Ping introduced innovative marketing strategies, such as in-store competitions and training for pharmacy staff, which were unprecedented in the industry at the time [5]. - He recognized the challenges faced by pharmaceutical distributors due to shrinking profit margins and implemented a commission-based model in 2002 to enhance profitability for distributors [6]. - By 2004, the sales of the Dongsheng anti-cold family exceeded 50 million, with Bai Jia Hei achieving a record of 500 million [6].